Juventas

About:

Juventas is a provider and developer of innovative immune cell therapeutic drugs.

Top Investors: CICC, Delian Capital, CASI Pharmaceuticals, Dalton Venture, Panacea Venture

Description:

Juventas is a provider and developer of innovative immune cell therapeutic drugs. The company's first investigational new drug application for the cell therapeutic product CNCT19 has been officially accepted by the National Medical Products Administration. Comprehensive product pipelines will be developed and promoted constantly to provide effective treatment for malignant hematological neoplasms such as leukemia and lymphoma.

Total Funding Amount:

$102M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Chaoyang, Liaoning, China

Founded Date:

2018-01-01

Contact Email:

juventas(AT)juventas.cn

Founders:

Guang Ming Wang

Number of Employees:

51-100

Last Funding Date:

2021-07-12

IPO Status:

Private

Industries: